Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 18/20 | 1.00 |
| ▸ | PLA2G4C | Q9UP65 | 2/20 | 0.54 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222832 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL29380622 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL29862419 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL16908822 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL19689390 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL1684101 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22222829 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22187692 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22222878 | 0.93 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL3690078 | 0.93 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2614144-B1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION | TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2015-07-22 | — | — | EP | claimed |
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | claimed |
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2012055814-A1 | COMPOUND INDUCING LBPA ACCUMULATION FOR INHIBITING CELL-TO-CELL TRANSMISSION OF HIV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-05-03 | — | — | WO | claimed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| EP-2614144-B1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION | TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-20130209403-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTION | RUPRECHT-KARLS-UNIVERSITAET (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012055814-A1 | COMPOUND INDUCING LBPA ACCUMULATION FOR INHIBITING CELL-TO-CELL TRANSMISSION OF HIV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-05-03 | — | — | WO | disclosed |